| Name | LR-90 |
| Description | LR-90, an advanced glycation end product (AGE) inhibitor, is utilized in diabetic animal model research. This compound effectively suppresses inflammatory responses in human monocytes. |
| In vitro | LR-90 (0, 25, 50, 100, and 200 μM) significantly blocks THP-1 cell adherence to endothelial cells in a dose-dependent manner after 1-hour pretreatment followed by S100b stimulation for 24 hours, without affecting THP-1 cell viability. Additionally, LR-90 inhibits RAGE, MCP-1, COX-2, IP-10, and NOX2 mRNA expression in THP-1 cells dose-dependently after 1-hour pretreatment before S100b stimulation for 4 hours[1]. |
| In vivo | LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation[2].LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (4.65 mM), Sonication is recommended. DMSO : 95 mg/mL (133.88 mM), Sonication is recommended.
|
| Keywords | LR-90 | LR90 | LR 90 | Inhibitor | inhibit | AGE |
| Inhibitors Related | Naproxen sodium | Acetaminophen | Phenidone | 4-Aminosalicylic acid | Gallic Acid Monohydrate | Diclofenac Potassium | Indomethacin | Paradol | Trometamol | 5-Methylfurfural | Phenylbutazone | Magnesium sulfate |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Anti-Diabetic Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |